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ORIGINAL ARTICLE – COLORECTAL CANCER
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ABSTRACT
Background. Controversy exists on emergency setting as
a risk factor for peritoneal metastases (PM) in colon cancer
patients. Data in patients with obstruction are scarce. The
aim of this study was to determine the incidence of syn-
chronous and metachronous PM, risk factors for the
development of metachronous PM, and prognostic impli-
cations within a large nationwide cohort of left-sided
obstructive colon cancer (LSOCC).
Methods. Patients with LSOCC treated between 2009 and
2016 were selected from the Dutch ColoRectal Audit.
Additional treatment and long-term outcome data were
retrospectively collected from original patient files in 75
hospitals in 2017.
Results. In total, 3038 patients with confirmed obstruction
and without perforation were included. Synchronous PM
(at diagnosis or\ 30 days postoperatively) were
diagnosed in 148/2976 evaluable patients (5.0%), and
3-year cumulative metachronous PM rate was 9.9%. Mul-
tivariable Cox regression analyses revealed pT4 stage (HR
1.782, 95% CI 1.191–2.668) and pN2 stage (HR 2.101,
95% CI 1.208–3.653) of the primary tumor to be inde-
pendent risk factors for the development of metachronous
PM. Median overall survival in patients with or without
synchronous PM was 20 and 63 months (p\ 0.001) and
3-year overall survival of patients that did or did not
develop metachronous PM was 48.1% and 77.0%,
respectively (p\ 0.001).
Conclusion. This population based study revealed a 5.0%
incidence of synchronous peritoneal metastases in patients
who underwent resection of left-sided obstructive colon
cancer. The subsequent 3-year cumulative metachronous
PM rate was 9.9%, with advanced tumor and nodal stage as
independent risk factors for the development of PM.
Colorectal cancer is the third most common malignancy
worldwide. In these patients, the peritoneum is the second
most common place of recurrence.1,2 Published incidence
rates of metachronous PM are influenced by characteristics
of the colorectal cancer population, as well as the method
of detection. Sensitivity of imaging is low for the small flat
peritoneal lesions, and metachronous PM might remain
undetected unless surgical re-exploration is performed.3
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Consequently, incidences may be underestimated. Prog-
nosis is generally poor at time of diagnosis, with a median
survival of approximately 5 months when untreated.4,5
Published risk factors for the development of meta-
chronous PM in colorectal cancer are advanced tumor
(T) and nodal (N) status, mucinous histology, emergency
surgery, and non-radical resection of the primary tumor.6,7
Emergency surgery is mostly performed for either tumor
perforation, obstruction, or bowel perforation proximal to
an obstructing cancer. In a systematic review by Honoré
et al., tumor perforation was identified as a risk factor for
metachronous PM. Regarding obstruction, the authors
stated that no increased risk for the development of meta-
chronous PM was reported in 12 large series, although this
association was not part of the aims of these studies.8 The
authors updated their review in 2017, and no new data to
modify their conclusion on obstruction as a risk factor for
peritoneal recurrence was available.9
In 2017, a nationwide collaborative research project on
left-sided obstructing colon cancer (LSOCC) was per-
formed in the Netherlands.10 Given the paucity of data on
PM in patients with obstructing colon cancer, the primary
aim of this study was to determine the incidence of syn-
chronous PM and cumulative metachronous PM rate using
this large dataset. Secondary objectives were to provide
independent predictors of metachronous PM in this patient




A collaborative, national research project was per-
formed by the Dutch Snapshot Research Group (DSRG)
according to a previously published protocol.10 Short-term
data of patients with a registered resection of LSOCC
between 2009 and 2016 were retrieved from the Dutch
Colorectal Audit (DCRA). In this national, prospective
(mandatory) database, all patients with colorectal cancer
had undergone either emergency or elective surgical
resection for primary colorectal cancer. Left-sided resec-
tions were defined as resection for a tumor located in the
splenic flexure, descending colon or sigmoid. Additional
baseline, procedural, and long-term outcome data were
retrospectively gathered from original patient files by sur-
gical residents between August and December 2017.11 The
design of this study and preparation of the manuscript were
performed according to the Strengthening The Reporting of
Observational Studies in Epidemiology (STROBE)
guidelines.12
Inclusion/Exclusion Criteria
After collection of additional diagnostic data from the
original patient files, only patients with a documented
symptomatic colonic obstruction with complaints of either
nausea, vomiting, and/or abdominal distention with con-
firmation of the obstruction on X-ray or computed
tomography (CT) were considered as a diagnosis of
LSOCC. Patients without proven malignancy, an extra-
colonic malignancy, and/or signs of bowel perforation on
CT at baseline were excluded.
Outcome Parameters and Definitions
The main outcomes of this study were the incidence of
synchronous PM and cumulative metachronous PM rate.
Secondary outcomes included risk factors for the devel-
opment of metachronous PM, and treatment of PM.
Synchronous PM were defined as PM present at time of
diagnosis or observed within 30 days after resection of the
primary tumor according to Segelman et al.6 Metachronous
PM included PM observed after 30 days following primary
tumor resection. For analyses of synchronous PM, all
patients were included independent of intention of treat-
ment. For analyses of metachronous PM, patients were
excluded if they had synchronous PM, palliative treatment
intent post-resection, palliative treatment intent based on
review of original patient files, or if patients died within
30 days postoperatively. For synchronous PM, overall
survival included the interval between first presentation
and death by any cause, or last follow-up. For metachro-
nous PM, overall survival was defined as the interval from
primary tumor resection until death by any cause or last
follow-up. Treatment was categorized as cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy
(CRS/HIPEC) or other modalities.
Statistical Analysis
Normally distributed continuous outcomes are reported
as means with standard deviation (SD) and analysed with
Student’s t test. Non-normally distributed continuous data
are shown as medians with interquartile range (IQR) and
compared with the Mann–Whitney U test. Categorical
variables are presented as percentages and compared with
the X2 test or Fisher’s exact test. Kaplan–Meier analysis
was used to determine the cumulative metachronous PM
rate. To determine independent risk factors for the devel-
opment of metachronous PM, Cox regression analyses
were performed. Covariates were included in the univari-
able Cox regression analysis based on previous literature in
combination with initial analyses of baseline and proce-
dural characteristics. Covariates with a p-value of\ 0.2
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after univariable analysis were included in the multivari-
able Cox regression model to identify individual risk
factors for the development of metachronous PM. Overall
survival was calculated and plotted using Kaplan–Meier
analysis for the different predefined subgroups and com-
pared using the log-rank test. A two-sided p value
of\ 0.05 was considered statistically significant. Analyses
were performed with IBM SPSS statistics, version 25.0
(IBM Corp Amonk, NY, USA).
Ethics
The Institutional Review Board of the Academic Med-
ical Center in Amsterdam (the Netherlands) approved this
study, with exemption status for individual informed con-




Of the 77 hospitals in the Netherlands in 2017, 75
hospitals participated, resulting in a registration of 3879
potentially eligible patients (Fig. 1). After applying strict
inclusion criteria, mainly related to a confirmed diagnosis
of acute colonic obstruction without signs of bowel per-
foration, 3038 patients remained for analysis on
synchronous PM. A total of 2407 patients were included
for analyses on metachronous PM, after exclusion of
patients with synchronous PM (N = 148), patients with
palliative intention of treatment (N = 367), and patients
who died within 30 days after resection (N = 116).
Synchronous Peritoneal Metastases
Baseline and Procedural Characteristics Presence of PM
at diagnosis of the primary tumor or until 30 days
postoperatively was missing in 62 of 3038 patients
(2.0%). Of the remaining 2976 patients, synchronous PM
were present in 148 patients (5.0%). The peritoneum was
the only site of metastatic disease in 67 patients (45.6%).
Patients with synchronous PM were significantly younger
(median 66 vs. 71 years, p\ 0.001), and more often had a
pT4 stage (63.0% vs. 27.9%, p\ 0.001) and pN2 stage
(54.2% vs. 21.6%, p\ 0.001) when compared to patients
without synchronous PM (Table 1). Resection of the
primary tumor was more often incomplete in the
synchronous PM group (13.4% vs. 4.3%, p\ 0.001).
Treatment and Survival of Synchronous PM Median
follow-up of the entire cohort was 26 months (IQR 12–47).
Median overall survival was 20 months (95% CI 17–23) in
patients with synchronous PM and 63 months (95% CI
58–68) for patients without synchronous PM (p\ 0.001)
(Fig. 2). Three-year overall survival rates were 18.8% and
64.0%, respectively. After diagnosis of synchronous PM,
25 patients (17.0%) were treated with CRS/HIPEC.
Metachronous Peritoneal Metastases
Baseline and Procedural Characteristics Data on
peritoneal recurrence were missing in 115 of 2407
patients (4.8%). Metachronous PM developed in 210 of
the 2292 evaluable patients after a median interval from
primary tumor resection of 14 months (IQR 9.0–22.0). The
cumulative metachronous PM rate at 1, 2 and 3 years was
3.8%, 8.0%, and 9.9%, respectively. Baseline
characteristics stratified for metachronous PM are
displayed in Table 2. Patients with metachronous PM
were significantly younger (69 vs. 71 years, p\ 0.001),
were less often ASA III-IV (22.6% vs. 30.5%, p = 0.017),
and fewer patients had comorbidities (62.4% vs. 70.8%,
p = 0.012). Metachronous PM patients were more often
diagnosed with pT4 stage (39.7% vs. 24.7%, p\ 0.001)
and pN2 stage (29.2% vs. 17.1%, p\ 0.001), and had a
higher proportion of incomplete resection (6.0% vs. 3.3%,
p = 0.067). More patients in the metachronous PM group
were treated with adjuvant systemic chemotherapy (52.9%
vs. 39.7%, p\ 0.001).
Risk Factors for the Development of Metachronous PM
in LSOCC Univariable analysis revealed the following
potential predictors of metachronous PM: subtotal
colectomy, pT4 stage, pN1 stage, pN2 stage, incomplete
(R1–2) resection, having received adjuvant chemotherapy,
and time from resection until adjuvant chemotherapy
of C 8 weeks (Table 3). Subsequent multivariable
analysis identified only pT4 stage (HR 1.78, 95% CI
1.19–2.67, p = 0.005) and pN2 stage (HR 2.10, 95% CI
1.21–3.65, p = 0.009) as independent risk factors.
Treatment and Survival of Metachronous PM Treatment
of metachronous PM was judged by the local investigators
as intentionally curative in 59 patients (28.6%)
(Supplementary Table 1), and this consisted of CRS/
HIPEC in 41 patients (19.9%). A total of 147 patients
(71.4%) were treated with palliative intent, mostly
comprising palliative systemic therapy. Median follow-up
was 31 months (IQR 15–52). Three-year overall survival
was 48.1% and 77.0% for patients developing
metachronous PM and patients who did not, respectively
(p\ 0.001) (Fig. 3).
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DISCUSSION
The present population based analysis of patients who
underwent resection of LSOCC revealed an incidence of
synchronous PM of 5%. The cumulative 3-year meta-
chronous PM rate of the remaining patients who were
treated with curative intent and were still alive at 30 days
postoperatively was 9.9%. Within this clearly defined
cohort of colon cancer patients who present with an
emergency obstruction, pT4 and pN2 stage appeared to be
independent risk factors for developing metachronous PM.
A substantial prognostic impact of both synchronous and
metachronous PM could be demonstrated. In both the
synchronous and metachronous PM groups, less than 20%
were eligible for surgical treatment of PM.
There are a few other population based studies on
incidence of synchronous PM of colorectal origin. Another
Dutch study from the Eindhoven Cancer registry found an
incidence of 4.8% among 18,738 patients diagnosed with
primary colorectal cancer between 1995 and 2008, of
whom 44% had metastatic disease limited to the peritoneal
cavity.13 The definition of synchronous PM was not pro-
vided and no data were given on emergency presentation.
This incidence was confirmed at a national level by Van
der Geest et al., reporting a 4.7% synchronous PM rate
between 2008 and 2011.14 Synchronous PM were found in
477 of 11,124 colorectal cancer patients (4.3%) in the
Stockholm region (1995–2007) within 1 month from
diagnosis.6 This study did not provide separate data on
emergency surgery or obstruction. A recent study based on
the entire country of Sweden, including 35,120 colorectal
and appendiceal cancers surgically treated between 2007
and 2015, reported a 2.5% incidence of synchronous PM
within 6 months from diagnosis.7 Perforation close to a
colon cancer was only statistically significant in univari-
able analysis, but emergency surgery for colon cancer
remained independently associated with synchronous PM
in multivariable analysis. An overall incidence of syn-
chronous PM of 6.8% was reported in a French study
including 9148 colorectal cancer patients (1976–2011)
Patients identified from the Dutch Colorectal Audit 2009-2016 
N = 4216
Excluded (N = 726)
- No acute obstruction N=670
- No resection N=23
- Benign obstruction N=17
- Palliative stent N=5
- Unknown patient N=2
- Rectal cancer N=4
- Date of surgery <2009 N=4
- Duplicate record N=1
Number of patients with left-sided obstructing colon cancer
N = 3153
Registered patients in collaborative research project
N = 3879
Study population for synchronous peritoneal metastases 
analyses without signs of perforation
N = 3038
Excluded (N = 115)
- Free air on CT (N=115)
Study population for metachronous peritoneal 
metastases analyses 
N = 2407
Excluded (N = 631)
- Synchronous peritoneal 
metastases N=148
- Palliative treatment intent of 
acute obstruction N=367
- Died < 30 days after 
resection N=116
FIG. 1 Patient selection
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TABLE 1 Baseline and surgical characteristics of patients who underwent resection of left-sided obstructive colon cancer, stratified for
detection of synchronous peritoneal metastases
Synchronous peritoneal
metastases
N = 148 (%)
No synchronous peritoneal
metastases
N = 2828 (%)
P
Sex (N = 2976) 0.493
Male 86/148 (58.1) 1562/2828 (55.2)
Female 62/148 (41.9) 1266/2828 (44.8)
Median age in years (i.q.r) (N = 2976) 66.0 (60.0–75.0) 71.0 (62.0–79.0) \ 0.001
Mean BMI in kg/m2 (SD) (N = 2516) 24.8 (3.9) 25.4 (4.3) 0.103
ASA score (N = 2947) 0.788
ASA I-II 99/145 (68.3) 1883/2802 (67.2)
ASA III-IV 46/145 (31.7) 919/2802 (32.8)
Comorbidity (N = 2961) 102/145 (70.3) 1981/2816 (70.3) 0.999
Previous abdominal surgery (N = 2948) 33/146 (22.6) 840/2802 (30.0) 0.057
Tumour localization (N = 2976) 0.487
Sigmoid 106/148 (71.6) 1956/2828 (69.2) 0.528
Descending colon 21/148 (14.2) 508/2828 (18.0) 0.242
Splenic flexure 21/148 (14.2) 364/2828 (12.9) 0.641
Tumour histology (N = 2927) 0.023
Adenocarcinoma 133/143 (93.0) 2660/2784 (95.5) 0.157
Mucinous tumour 6/143 (4.2) 105/2784 (3.8) 0.796
Signet-ring cell tumour 4/143 (2.8) 12/2784 (0.4) 0.006
Other 0/143 (0.0) 7/2784 (0.3) 1.000
Tumour differentiation (N = 1924) 0.010
Well/moderate 78/93 (83.9) 1689/1831 (92.2)
Poor 15/93 (16.1) 142/1831 (7.8)
Median no. of lymph nodes harvested (i.q.r.) (N = 2961) 16.0 (12.0–21.0) 15.0 (11.0–21.0) 0.311
Median no. of positive lymph nodes (i.q.r.) (N = 2958) 4.0 (1.0–9.0) 1.0 (0.0–3.0) \ 0.001
pT stage (N = 2960) \ 0.001
pT1 1/146 (0.7) 7/2814 (0.2) 0.333
pT2 4/146 (2.7) 104/2814 (3.7) 0.548
pT3 49/146 (33.6) 1918/2814 (68.2) \ 0.001
pT4 92/146 (63.0) 785/2814 (27.9) \ 0.001
pN stage (N = 2950) \ 0.001
pN0 22/144 (15.3) 1229/2806 (43.8) \ 0.001
pN1 44/144 (30.6) 970/2806 (34.6) 0.323
pN2 78/144 (54.2) 607/2806 (21.6) \ 0001
Synchronous distant metastases outside the peritoneal cavity
(N = 2969)
80/147 (54.4) 516/2822 (18.3) \ 0.001
Liver 70/147 (47.6) 460/2775 (16.6) \ 0.001
Lung 24/144 (16.7) 102/2763 (3.7) \ 0.001
Other 17/142 (12.0) 37/2751 (1.3) \ 0.001
Initial intervention for acute colonic obstruction (N = 2976) 0.422
Emergency resection 121/148 (81.8) 2231/2828 (78.9) 0.404
Decompressing stoma 20/148 (13.5) 359/2828 (12.7) 0.771
SEMS without SEMS-related perforation 6/148 (4.1) 214/2828 (7.6) 0.111
SEMS with SEMS-related perforation 1/148 (0.7) 24/2828 (0.8) 1.000
Initial treatment intent \ 0.001
Curative 64/148 (43.2) 2461/2828 (87.0)
Palliative 84/148 (56.8) 367/2828 (13.0)
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from the administrative area of Côte-d’Or in Burgundy,
also using a 6-month period from diagnosis of the primary
cancer. Among 737 patients with obstructing colorectal
cancer, the incidence of synchronous PM was 16.2%, with
a corresponding odds ratio for obstruction of 2.8 when





N = 148 (%)
No synchronous peritoneal
metastases
N = 2828 (%)
P
Laparoscopic approach for tumour resection (N = 2960) 19/147 (12.9) 454/2813 (16.1) 0.300
Conversion (N = 426) 5/17 (29.4) 104/409 (25.4) 0.777
Type of resection (N = 2975) 0.878
Sigmoid resection 98/148 (66.2) 1808/2827 (64.0) 0.576
Left hemicolectomy 38/148 (25.7) 756/2827 (26.7) 0.775
Subtotal colectomy 11/148 (7.4) 200/2827 (7.1) 0.869
Extended left hemicolectomy 0/148 (0.0) 22/2827 (0.8) 0.624
Combined sigmoid resection and right hemicolectomy 0/148 (0.0) 25/2827 (0.9) 0.633
Transverse colectomy 1/148 (0.7) 16/2827 (0.6) 0.581
Primary anastomosis (N = 2515) 58/148 (39.2) 1324/2817 (47.0) 0.063
Stoma in situ directly after resection (N = 2929) 103/144 (71.5) 1759/2785 (63.2) 0.042
Completeness of resection (N = 2873)
R0 110/127 (86.6) 2628/2746 (95.7)
R1–2 17/127 (13.4) 118/2746 (4.3) \ 0.001
Median follow-up in months (i.q.r.) (N = 2909) 16.0 (7.0–27.0) 27.0 (12.0–48.0) \ 0.001
SEMS self-expandable metal stent, SD standard deviation, i.q.r. interquartile range, BMI body mass index, ASA American Society of
Anaesthesiologists
Number at risk
Synchronous PM                    142                        98                       57                         28            12
No synchronous PM              2760                     2193                   1713                     1274 896


















FIG. 2 Overall survival in
patients with versus without
synchronous peritoneal
metastases
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TABLE 2 Baseline and surgical characteristics of patients who underwent curative intent resection of left-sided obstructive colon cancer, and
who developed metachronous peritoneal metastases beyond 30 days postoperatively versus those who did not
Metachronous peritoneal
metastases
N = 210 (%)
No metachronous peritoneal
metastases
N = 2082 (%)
P
Sex (N = 2292) 0.207
Male 104/210 (49.5) 1126/2082 (54.1)
Female 106/210 (50.5) 956/2082 (45.9)
Median age in years (i.q.r) (N = 2292) 69.0 (61.0–76.0) 71.0 (62.0–78.0) \ 0.001
Mean BMI in kg/m2 (SD) (N = 2008) 25.4 (23.2–28.4) 24.9 (22.7–27.6) 0.081
ASA score (N = 2269) 0.017
ASA I-II 161/208 (77.4) 1432/2061 (69.5)
ASA III-IV 47/208 (22.6) 629/2061 (30.5)
Comorbidity (N = 2283) 131/210 (62.4) 1467/2073 (70.8) 0.012
Previous abdominal surgery (N = 2272) 52/207 (25.1) 635/2065 (30.8) 0.093
Tumour localization (N = 2292) 0.609
Sigmoid 140/210 (66.7) 1421/2082 (68.3) 0.639
Descending colon 38/210 (18.1) 394/2082 (18.9) 0.770
Splenic flexure 32/210 (15.2) 267/2082 (12.8) 0.322
Tumour histology (N = 2253) 0.003
Adenocarcinoma 188/208 (90.4) 1962/2045 (95.9) \ 0.001
Mucinous tumour 16/208 (7.7) 72/2045 (3.5) 0.003
Signet-ring cell tumour 2/208 (1.0) 7/2045 (0.3) 0.199
Other 2/208 (1.0) 4/2045 (0.2) 0.099
Tumour differentiation (N = 1487) 0.758
Well/moderate 122/132 (92.4) 1262/1355 (93.1)
Poor 10/132 (7.6) 93/1355 (6.9)
Median no. of lymph nodes examined (i.q.r.) (N = 2286) 14.0 (11.0–20.0) 15.0 (12.0–21.0) 0.064
Median no. of positive lymph nodes (i.q.r.) (N = 2281) 2.0 (0.0–4.0) 1.0 (0.0–2.0) \ 0.001
pT stage (N = 2282) \ 0.001
pT1 1/209 (0.5) 5/2073 (0.2) 0.438
pT2 5/209 (2.4) 86/2073 (4.1) 0.216
pT3 120/209 (57.4) 1471/2073 (71.0) \ 0.001
pT4 83/209 (39.7) 511/2073 (24.7) \ 0.001
pN stage (N = 2277) \ 0.001
pN0 72/209 (34.4) 1015/2068 (49.1) \ 0.001
pN1 76/209 (36.4) 700/2068 (33.8) 0.465
pN2 61/209 (29.2) 353/2068 (17.1) \ 0.001
Synchronous distant metastases outside the peritoneal cavity
(N = 2241)
23/208 (11.1) 161/2033 (7.9) 0.116
Liver 22/208 (10.6) 138/2030 (6.8) 0.044
Lung 1/208 (0.5) 19/2030 (0.9) 1.000
Other 0/208 (0.0) 15/2028 (0.7) 0.387
Initial intervention for acute colonic obstruction (N = 2292) 0.802
Emergency resection 169/210 (80.5) 1602/2082 (76.9) 0.245
Decompressing stoma 25/210 (11.9) 291/2082 (14.0) 0.406
SEMS without SEMS-related perforation 15/210 (7.1) 174/2082 (8.4) 0.542
SEMS with SEMS-related perforation 1/210 (0.5) 15/2082 (0.7) 1.000
Laparoscopic approach for tumour resection (N = 2280) 33/209 (15.8) 347/2071 (16.8) 0.721
Conversion (%) (N = 339) 6/32 (18.8) 80/307 (26.1) 0.366
Type of resection (N = 2291) 0.238
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The present cohort represents a certain subpopulation
with only left-sided obstructing tumors. Left-sided location
has been associated with lower risk of PM, whereas
emergency setting and the more advanced T as well as N
stage would imply a higher risk of PM if compared to an
unselected colon cancer population. The 5.0% observed
incidence of synchronous PM in the current study is dif-
ficult to compare with the available literature, given the
varying definitions (PM diagnosed within 1–6 months),
populations and time periods that were included. Using the
same definition regarding diagnosis within 1 month from
primary resection, the incidence of the current population
with obstruction is probably only slightly higher if com-
pared with the unselected population of Segelman et al.6
Reported survival of synchronous PM based on registry
data is generally poor, ranging from a median survival of
5 months in older studies and in combination with other
metastatic sites, up to a 3-year overall survival rate of 21%
with surgical treatment in more recent years.13,15 Besides
surgical treatment, mostly consisting of CRS/HIPEC, the
use of systemic therapy has also substantially increased
over the years, which translated into better survival at a
population level.15,16
The 3-year metachronous PM rate of 9.9% as found in
our selected population constituting left-sided obstructing
colon cancer, seems substantially higher compared to
unselected colon cancer populations described in the lit-
erature. A recent pooled analysis of three large randomized
trials on adjuvant treatment after curative resection of stage
II-III colon cancer revealed an overall crude incidence of
only 2.3% (86/3714).17 Younger age (\ 60 years), pT4,
pN1–2 and D2 (instead of D3) lymphadenectomy were
found to be independent predictors for metachronous PM,
while adjuvant chemotherapy, mucinous histology and
differentiation were not associated. The authors explain the
relatively low rate of metachronous PM by the fact that no
perforated tumors were included in these trials, with very
low rates of obstruction, emergency surgery and incom-
plete resection.
A previous Dutch population based study reported a
crude incidence of metachronous PM of 3.4% (197/
5671).18 No data on emergency setting was available. One
of the reasons for the higher percentage of PM in the
present study might be the fact that this is a more recent
cohort of patients. Over the years, the use of CT imaging
during follow-up has intensified and the quality of CT
imaging has improved. A similar 4.2% metachronous PM
rate was found in the previously mentioned study from
Stockholm County.6 Emergency surgery was associated
with higher risk of metachronous PM. Although reasons for
emergency surgery were not reported, bowel perforation




N = 210 (%)
No metachronous peritoneal
metastases
N = 2082 (%)
P
Sigmoid resection 121/210 (57.6) 1324/2081 (63.6) 0.087
Left hemicolectomy 65/210 (31.0) 582/2081 (28.1) 0.376
Subtotal colectomy 19/210 (9.0) 131/2081 (6.3) 0.124
Extended left hemicolectomy 1/210 (0.5) 18/2081 (0.9) 1.000
Combined sigmoid resection and right hemicolectomy 2/210 (1.0) 16/2081 (0.8) 0.678
Transverse colectomy 2/210 (1.0) 8/2081 (0.4) 0.232
Primary anastomosis (N = 2283) 94/209 (45.0) 1014/2074 (48.9) 0.280
Stoma in situ directly after resection (N = 2255) 135/207 (65.2) 1263/2048 (61.7) 0.316
Completeness of resection (%) (N = 2237) 0.067
R0 189/201 (94.0) 1969/2036 (96.7)
R1–2 12/201 (6.0) 67/2036 (3.3)
Adjuvant chemotherapy (N = 2286) 110/208 (52.9) 826/2078 (39.7) \ 0.001
Median time in weeks from resection until start adjuvant
chemotherapy (i.q.r.) (N = 838)
6.0 (4.0–11.0) 6.0 (4.0–8.0) 0.435
Median follow-up in months (i.q.r.) (N = 2245) 26.0 (16.5–39.0) 32.0 (16.0–54.0) 0.006
SEMS self-expandable metal stent, SD standard deviation, i.q.r. interquartile range, BMI body mass index, ASA American Society of
Anaesthesiologists
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TABLE 3 Cox proportional hazards regression analysis of risk factors for developing metachronous peritoneal metastases after resection of left-
sided obstructive colon cancer
Variable Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
Age
\ 60 years Reference
C 60 years 0.905 (0.651–1.259) 0.554 – –
ASA score
ASA 1–2 Reference
ASA 3–4 0.828 (0.598–1.147) 0.257 – –
Treatment
Emergency resection Reference
Elective resection after DS or SEMS without perforation 0.809 (0.571–1.146) 0.232 – –
SEMS with perforation 0.651 (0.091–4.653) 0.669
Surgical approach
Open Reference
Laparoscopic 0.932 (0.639–1.358) 0.713 – –
Type of resection
Segmental resection Reference
Subtotal colectomy 1.597 (0.996–2.560) 0.052 NS NS
Major post-resection complications
No Reference
Yes 0.933 (0.627–1.390) 0.735 – –
Tumour histology
Non-mucinous Reference
Mucinous 2.383 (1.430–3.973) 0.001 NS NS
pT stage
pT1–3 Reference Reference
pT4 2.176 (1.646–2.876) \ 0.001 1.782 (1.191–2.668) 0.005
pN stage
pN0 Reference Reference
pN1 1.557 (1.127–2.152) 0.007 1.207 (0.696–2.094) 0.503
pN2 2.599 (1.844–3.662) \ 0.001 2.101 (1.208–3.653) 0.009
Location of tumour
Splenic flexure Reference – –
Descending colon 0.848 (0.528–1.361) 0.495
Sigmoid 0.842 (0.573–1.236) 0.379
Radicality
R0 Reference
R1–2 2.141 (1.194–3.840) 0.011 NS NS
Adjuvant chemotherapy
No Reference
Yes 1.389 (1.056–1.825) 0.019 NS NS
Time from resection until adjuvant chemotherapy
\ 8 weeks Reference
C 8 weeks 1.314 (0.874–1.975) 0.189 NS NS
ASA American Society of Anaesthesiologists, DS decompressing stoma, SEMS self-expandable metal stent, NS not significant
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not show a significant association. The more recent data
from Sweden confirmed that perforation was not associated
with metachronous PM, while emergency surgery for colon
cancer was independently associated with metachronous
PM (HR 1.92).7 The French study by Quere et al. reported
an overall cumulative incidence of metachronous PM of
5.5% at 5 years.15 Obstruction or perforation were both
associated with a 10% and 12% cumulative risk of meta-
chronous PM at 3 and 5 years, respectively, with a
corresponding combined HR of 1.82 in multivariable
analysis. Our study confirms these observations and sup-
ports the hypothesis that obstruction is an independent risk
factor for metachronous PM.
Remarkably, observed HR for T4 of 1.8 and for N2 of
2.1 in the present study are much lower than in the pub-
lished multivariable models. Segelman et al. developed a
prediction model for colon and rectal cancer separately,
which was subsequently validated.19,20 Right-sided tumor
location (HR 1.23), number of harvested lymph nodes\
12 (HR 1.64), R1 resection (HR 1.49), R2 resection (HR
2.31) and emergency surgery (HR 2.09) were of minor
influence, whereas the highest risk was observed for T4
(HR 19.44) and N2 stage (HR 4.51). External validation
resulted in modification of the model with incorporation of
mucinous histology, but still showing the two dominant
predictors of T4 and N2 stage. The relatively low HRs as
found in the present analysis are likely explained by a
higher a priori risk, mainly caused by more advanced T and
N stage at baseline. This might also support the finding of
the French study that obstruction itself increases the risk of
metachronous PM, after which the impact of TN stage is
reduced.
The literature suggests that more intensified surgical and
systemic treatment in selected patients with metachronous
PM results in favourable survival.15,16 However, the pro-
portion of patients that are eligible for multimodality
treatment including surgery is still restricted based on the
present study, emphasizing the need for studies that aim for
optimized detection and management of metachronous
PM.21
Limitations of the present study are related to the ret-
rospective data collection and some degree of missing data.
For example, treatment of synchronous PM was registered
inconsistently with consequent limited information. Fur-
thermore, the relative contribution of obstruction to the risk
of synchronous or metachronous PM could not be deter-
mined because of the lack of a control group. Another
important limitation is the difficulty of diagnosing PM with
standard imaging techniques. For example, the incidence of
PM in CRC patients undergoing post-mortem autopsy is
even up to 40%, depending on tumour type (mucinous and
signet ring cell vs. adenocarcinoma) and location.22 Nev-
ertheless, this study adds to the currently available
literature by providing up to date epidemiological data on
peritoneal dissemination in patients with LSOCC.
In conclusion, this population based study revealed a
5.0% incidence of synchronous peritoneal metastases in
patients who underwent resection of left-sided obstructive
colon cancer. The subsequent 3-year cumulative meta-
chronous PM rate was 9.9%, with advanced tumour and
nodal stage as independent risk factors for the development
of PM. This relatively high rate supports the literature
suggesting that obstruction is independently associated
with an increased risk of metachronous PM.
Number at risk 
Metachronous PM            206                       183                      134                        91                    49
No metachronous PM      2057                     1756                    1400                     1098                     805 


















FIG. 3 Overall survival in
patients who did or did not
develop metachronous
peritoneal metastases as
measured from time of primary
tumour resection
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